These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 23999545)

  • 1. What is the role of the D3 receptor in addiction? A mini review of PET studies with [(11)C]-(+)-PHNO.
    Payer D; Balasubramaniam G; Boileau I
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jul; 52():4-8. PubMed ID: 23999545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imaging the D3 dopamine receptor across behavioral and drug addictions: Positron emission tomography studies with [(11)C]-(+)-PHNO.
    Boileau I; Nakajima S; Payer D
    Eur Neuropsychopharmacol; 2015 Sep; 25(9):1410-20. PubMed ID: 26141509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imaging dopamine D3 receptors in the human brain with positron emission tomography, [11C]PHNO, and a selective D3 receptor antagonist.
    Searle G; Beaver JD; Comley RA; Bani M; Tziortzi A; Slifstein M; Mugnaini M; Griffante C; Wilson AA; Merlo-Pich E; Houle S; Gunn R; Rabiner EA; Laruelle M
    Biol Psychiatry; 2010 Aug; 68(4):392-9. PubMed ID: 20599188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heightened Dopaminergic Response to Amphetamine at the D
    Boileau I; Payer D; Rusjan PM; Houle S; Tong J; McCluskey T; Wilson AA; Kish SJ
    Neuropsychopharmacology; 2016 Dec; 41(13):2994-3002. PubMed ID: 27353309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blockade of [11C](+)-PHNO binding in human subjects by the dopamine D3 receptor antagonist ABT-925.
    Graff-Guerrero A; Redden L; Abi-Saab W; Katz DA; Houle S; Barsoum P; Bhathena A; Palaparthy R; Saltarelli MD; Kapur S
    Int J Neuropsychopharmacol; 2010 Apr; 13(3):273-87. PubMed ID: 19751545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Higher binding of the dopamine D3 receptor-preferring ligand [11C]-(+)-propyl-hexahydro-naphtho-oxazin in methamphetamine polydrug users: a positron emission tomography study.
    Boileau I; Payer D; Houle S; Behzadi A; Rusjan PM; Tong J; Wilkins D; Selby P; George TP; Zack M; Furukawa Y; McCluskey T; Wilson AA; Kish SJ
    J Neurosci; 2012 Jan; 32(4):1353-9. PubMed ID: 22279219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopamine (D2/3) receptor agonist positron emission tomography radiotracer [11C]-(+)-PHNO is a D3 receptor preferring agonist in vivo.
    Narendran R; Slifstein M; Guillin O; Hwang Y; Hwang DR; Scher E; Reeder S; Rabiner E; Laruelle M
    Synapse; 2006 Dec; 60(7):485-95. PubMed ID: 16952157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated Dopamine D
    Gaiser EC; Gallezot JD; Worhunsky PD; Jastreboff AM; Pittman B; Kantrovitz L; Angarita GA; Cosgrove KP; Potenza MN; Malison RT; Carson RE; Matuskey D
    Neuropsychopharmacology; 2016 Dec; 41(13):3042-3050. PubMed ID: 27374277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopamine D3 Receptor Availability Is Associated with Inflexible Decision Making.
    Groman SM; Smith NJ; Petrullli JR; Massi B; Chen L; Ropchan J; Huang Y; Lee D; Morris ED; Taylor JR
    J Neurosci; 2016 Jun; 36(25):6732-41. PubMed ID: 27335404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opposing relationships of BMI with BOLD and dopamine D2/3 receptor binding potential in the dorsal striatum.
    Cosgrove KP; Veldhuizen MG; Sandiego CM; Morris ED; Small DM
    Synapse; 2015 Apr; 69(4):195-202. PubMed ID: 25664726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo quantification of regional dopamine-D3 receptor binding potential of (+)-PHNO: Studies in non-human primates and transgenic mice.
    Rabiner EA; Slifstein M; Nobrega J; Plisson C; Huiban M; Raymond R; Diwan M; Wilson AA; McCormick P; Gentile G; Gunn RN; Laruelle MA
    Synapse; 2009 Sep; 63(9):782-93. PubMed ID: 19489048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [¹¹C]-(+)-PHNO PET imaging of dopamine D(2/3) receptors in Parkinson's disease with impulse control disorders.
    Payer DE; Guttman M; Kish SJ; Tong J; Strafella A; Zack M; Adams JR; Rusjan P; Houle S; Furukawa Y; Wilson AA; Boileau I
    Mov Disord; 2015 Feb; 30(2):160-6. PubMed ID: 25641350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antipsychotic binding to the dopamine-3 receptor in humans: A PET study with [(11)C]-(+)-PHNO.
    Girgis RR; Xu X; Gil RB; Hackett E; Ojeil N; Lieberman JA; Slifstein M; Abi-Dargham A
    Schizophr Res; 2015 Oct; 168(1-2):373-6. PubMed ID: 26190300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. D3 receptor target engagement in humans with ABT-925 using [11C](+)-PHNO PET.
    Day M; Bain E; Marek G; Saltarelli M; Fox GB
    Int J Neuropsychopharmacol; 2010 Apr; 13(3):291-2. PubMed ID: 20196920
    [No Abstract]   [Full Text] [Related]  

  • 15. Estimating the effect of endogenous dopamine on baseline [(11) C]-(+)-PHNO binding in the human brain.
    Caravaggio F; Kegeles LS; Wilson AA; Remington G; Borlido C; Mamo DC; Graff-Guerrero A
    Synapse; 2016 Nov; 70(11):453-60. PubMed ID: 27341789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationships between dopamine D2/3 receptor availability and social-environmental factors in humans.
    Calakos KC; Rusowicz A; Pittman B; Gallezot JD; Potenza MN; Cosgrove KP; Matuskey D
    Neurosci Lett; 2022 Feb; 771():136463. PubMed ID: 35051435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Within-subject comparison of [(11)C]-(+)-PHNO and [(11)C]raclopride sensitivity to acute amphetamine challenge in healthy humans.
    Shotbolt P; Tziortzi AC; Searle GE; Colasanti A; van der Aart J; Abanades S; Plisson C; Miller SR; Huiban M; Beaver JD; Gunn RN; Laruelle M; Rabiner EA
    J Cereb Blood Flow Metab; 2012 Jan; 32(1):127-36. PubMed ID: 21878947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imaging nicotine- and amphetamine-induced dopamine release in rhesus monkeys with [(11)C]PHNO vs [(11)C]raclopride PET.
    Gallezot JD; Kloczynski T; Weinzimmer D; Labaree D; Zheng MQ; Lim K; Rabiner EA; Ridler K; Pittman B; Huang Y; Carson RE; Morris ED; Cosgrove KP
    Neuropsychopharmacology; 2014 Mar; 39(4):866-74. PubMed ID: 24220025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of antipsychotics on D3 receptors: a clinical PET study in first episode antipsychotic naive patients with schizophrenia using [11C]-(+)-PHNO.
    Mizrahi R; Agid O; Borlido C; Suridjan I; Rusjan P; Houle S; Remington G; Wilson AA; Kapur S
    Schizophr Res; 2011 Sep; 131(1-3):63-8. PubMed ID: 21684721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The D2/3 dopamine receptor in pathological gambling: a positron emission tomography study with [11C]-(+)-propyl-hexahydro-naphtho-oxazin and [11C]raclopride.
    Boileau I; Payer D; Chugani B; Lobo D; Behzadi A; Rusjan PM; Houle S; Wilson AA; Warsh J; Kish SJ; Zack M
    Addiction; 2013 May; 108(5):953-63. PubMed ID: 23167711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.